UK life sciences company Isomorphic Labs has announced it has raised $2.1 billion to scale its AI drug design engine. 

The company raised the capital in a Series B financing round, which Isomorphic Labs says will accelerate the company’s evolution from pioneering novel AI models to applying them at scale. 

The financing round was led by Thrive Capital, with participation from Alphabet, Google’s parent company, as well as GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund. 

The investment will help develop and deploy Isomorphic Labs’ AI drug design engine, IsoDDE, which Isomorphic Labs claims offers a scalable foundation for AI drug design.  

Early results have shown the engine has the predictive fidelity required to navigate novel biological systems with unprecedented accuracy, introducing capabilities which bridge the gap between structure prediction and real-world drug discovery. 

Isomorphic Labs also plans to use the engine to expand its pipeline of therapeutic programmes towards the clinic. 

“This funding round is a massive vote of confidence from a diverse group of top-tier international investors in our AI-first approach to drug design and development,” said Sir Demis Hassabis, Founder and CEO.  

“Now that we have shown our approach is fundamentally sound, our focus is on scaling our technology to its full potential. This capital injection allows us to build out our drug design engine at scale, driving us forward in our mission to solve all disease.” 

“This milestone is built on the strength of our AI drug design engine, which has already proven its worth across our internal programs by hitting key milestones and identifying viable candidates with unprecedented speed,” added Max Jaderberg, President of Isomorphic Labs.  

“Our drug design engine works, and it’s giving us a repeatable way to design new medicines for a wide range of diseases, building a future of medicine that was previously out of reach.”